Concepedia

Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial

Robert J. Motzer, Thomas Powles, Mauricio Burotto, Bernard Escudier, María T. Bourlon, Amishi Y. Shah, Cristina Suárez, Alketa Hamzaj, Camillo Porta, Christopher Hocking,

The Lancet Oncology · 2022 · 307 citations · 19 references

DOIFull text

Open access

Concepts

References

19

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

Robert J. Motzer, Bernard Escudier, Saby George et al. · New England Journal of Medicine · 2015 · 5.9K citations · Full text

, , +17

THE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL

C. J. Clopper, E. S. Pearson · Biometrika · 1934 · 4.8K citations

, , +16

A Multiple Testing Procedure for Clinical Trials

Peter C. O’Brien, Thomas R. Fleming · Biometrics · 1979 · 3.3K citations

, , +13

Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma

Robert J. Motzer, B. Yа. Alekseev, Sun Young Rha et al. · New England Journal of Medicine · 2021 · 1.8K citations · Full text

, , +12

Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma

Toni K. Choueiri, Thomas Powles, Mauricio Burotto et al. · New England Journal of Medicine · 2021 · 1.7K citations · Full text

, , +9